Elimination of adipose tissue dysfunction as a major factor in reducing cardiometabolic risks in obesity


DOI: https://dx.doi.org/10.18565/therapy.2019.6.66-74

Ametov A.S., Rubtsov Yu.E., Saluhov V.V., Khalimov Yu.Sh., Agafonov P.V.

1) Russian medical Academy of continuous professional education of the Ministry of Healthcare of Russia, Moscow 2) S.M. Kirov Military medical Academy of the Ministry of Defense of the Russian Federation, Saint-Petersburg
Obesity is a growing health problem worldwide. This is associated with an increased cardiovascular risk, on the one hand, obesity itself, and on the other-related medical conditions (arterial hypertension, diabetes, insulin resistance and sleep apnea syndrome). Obesity and dysfunction of adipose tissue plays an important role in the development of atherosclerosis and coronary heart disease, leads to structural and functional changes in the heart, which leads to the development of heart failure, increases the risk of atrial fibrillation and sudden cardiac death. Recently completed studies on the effects of weight loss on cardiometabolic risks have demonstrated a convincing reduction in cardiovascular mortality in patients with obesity and type 2 diabetes. In this review, we will discuss different approaches to the effects on adipose tissue dysfunction, including lifestyle changes, medication, and bariatric surgery.
Keywords: adipose tissue dysfunction, cardiovascular risk, obesity
Read entire article

Literature


  1. Ng M. et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet. 2014; 384(9945): 766–81.

  2. Муромцева Г.А. с соавт. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012–2013 гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2014; 13(6): 4–11.

  3. World Health Organisation. Global Health Risks: mortality and burden of disease attributable to selected major risks (2009). http://www.who.int/healthinfo/global_burden_disease/global_health_risks/en/index.html World Health Organization Media Centre. Obesity and overweight. Fact sheet no Geneva: World Health Organization; 2013.

  4. James W.P.T., Jackson-Leach R., Mhurdu C.N. et al. Overweight and obesity. In comparative quantification of health risks: Global and regional burden of disease attributable to selected major risk factors. Eds. Ezzati M., Lopez A.D., Rodgers A., Murray C.J.L. WHO, Geneva, 2003.

  5. Ligibel J.A. et al. American Society of Clinical Oncology position statement on obesity and cancer. Journal of Clinical Oncology. 2014; 32(31): 3568–74.

  6. Yang W-S., Chen M-H., Lee W-J. et al. Adiponectin mRNA levels in the abdominal adipose depots of nondiabetic women. Int. J. Obesity. 2003; 27(8): 896–900.

  7. Jungheim E.S. et al. Obesity and reproductive function. Obstetrics and gynecology clinics of North America. 2012; 39(4): 479–93.

  8. Бирюкова Е.В., Соловьева И.В. Эффективная фармакотерапия ожирения – залог успешного лечения заболеваний, связанных с лишним весом. Эффективная фармакотерапия. Эндокринология. 2013; 3(29): 18–28.

  9. Hirsch J., Batchelor B. Adipose tissue cellularity in obesity. Clin Endocrinol Metab. 1976; 5(2): 299–311.

  10. Weisberg S.P., McCann D., Desai M. et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003; 112: 1796–1808.

  11. Xu H., Barnes G.T., Yang Q. et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003; 112: 1821–30.

  12. Fried S.K., Bunkin D.A., Greenberg A.S. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab. 1998; 83: 847–50.

  13. Steppan C.M., Bailey S.T., Bhat S. et al. The hormone resistin links obesity to diabetes. Nature. 2001; 409: 307–12.

  14. Miyazaki Y., Mahankali A., Matsuda M. etal. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care. 2001; 24: 710–19.

  15. Goldberg R.B., Kendall D.M., Deeg M.A. et al. GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005; 28: 1547–54.

  16. Straznicky N.E., Grima M.T., Sari C.I. et al. A randomised controlled trial of the effects of pioglitazone treatment on sympathetic nervous system activity and cardiovascular function in obese subjects with metabolic syndrome. J Clin Endocrinol Metab. 2014; 99: E1701–07.

  17. Miyazaki Y., Mahankali A., Matsuda M. et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2002; 87: 2784–91.

  18. Lean M.E.J., Leslie W.S., Barnes A.C. et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol. 2019 May; 7(5): 344–55.

  19. Tricco A.C., Ivers N.M., Grimshaw J.M. et al. Effectiveness of quality improvement strategies on the management of diabetes: a systematic review and meta-analysis. Lancet. 2012; 379: 2252–61.

  20. Del Prato S., Felton A.M., Munro N. et al. Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Int J Clin Pract. 2005; 59: 1345–55.

  21. Mudaliar S., Alloju S., Henry R.R. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A Unifying Hypothesis. Diabetes Care. 2016; 39(7): 1115–22.

  22. Ali M.K., Bullard K.M., Saaddine J.B. et al. Achievement of goals in U.S. diabetes care, 1999–2010. N Engl J Med. 2013; 368: 1613–24.

  23. North American Association for the Study of Obesity (NAASO) and the National Heart. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Bethesda, Md: National Institutes of Health; 1998. NIH publication 98–4083.

  24. The DCCT Research Group. Weight gain associated with intensive therapy in the Diabetes Control and Complications Trial. Diabetes Care. 1988; 11: 567–73.

  25. Yeo G., Heisler L. Unraveling the brain regulation of appetite: lessons from genetics. Nat Neurosci. 2012; 15: 1343–49.

  26. Lam D., Garfield A., Marston O. et al. Brain serotonin system in the coordination of food intake and body weight. Pharmacol Biochem Behav. 2010; 97: 84–91.

  27. Dedov I.I., Melnichenko G.A., Troshina E.A., Mazurina N.V., Galieva M.O. Body weight reduction associated with the sibutramine treatment: overall results of the PRIMAVERA primary health care trial. Obes Facts. 2018; 11: 335–43.

  28. Дедов И.И., Романцова Т.И., Шестакова М.В. Рациональный подход к терапии пациентов с СД 2 и ожирением: итоги всероссийской наблюдательной программы «АВРОРА». Ожирение и метаболизм. 2018; 15(4): 48–58.

  29. Ashrafian H., le Roux C.W., Darzi A., Athanasiou T. Effects of bariatric surgery on cardiovascular function. Circulation. 2008; 118: 2091–2102.

  30. Treadwell J.R., Turkelson C.M. Systematic review of bariatric surgery. JAMA. 2005; 293: 1726.

  31. Gloy V.L., Briel M., Bhatt D.L. et al. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ. 2013; 347: f5934.

  32. Vest A.R., Heneghan H.M., Schauer P.R. et al. Surgical management of obesity and the relationship to cardiovascular disease. Circulation. 2013; 127: 945–59.

  33. Sjostrom L., Peltonen M., Jacobson P. et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012; 307: 56–65.

  34. Adams T.D., Gress R.E., Smith S.C. et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007; 357: 753–61.

  35. Buchwald H., Avidor Y., Braunwald E. et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292: 1724–37.

  36. Rubino F., Schauer P.R., Kaplan L.M. et al. Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Annu Rev Med. 2010; 61: 393–411.

  37. Салухов В.В., Блэк М.С., Барсуков А.В. с соавт. Перспективы бариатрических вмешательств у пациентов с метаболическим синдромом. Consilium Medicum. 2017; 19 (10): 83–89.

  38. Heneghan H.M., Meron-Eldar S., Brethauer S.A. et al. Effect of bariatric surgery on cardiovascular risk profile. Am J Cardiol. 2011; 108: 1499–1507.

  39. Vest A.R., Heneghan H.M., Agarwal S. et al. Bariatric surgery and cardiovascular outcomes: a systematic review. Heart. 2012; 98:1763–77.

  40. Sjostrom L. Review of the key results from the Swedish Obese Subjects (SOS) trial – a prospective controlled intervention study of bariatric surgery (Review). J Intern Med. 2013; 273: 219–34.

  41. Plecka Ostlund M., Marsk R., Rasmussen F. et al. Morbidity and mortality before and after bariatric surgery for morbid obesity compared with the general population. British Journal of Surgery. 2011; 98: 811–16.

  42. Chang S.H., Stoll C.R., Song J. et al. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg. 2014; 149: 275–87.

  43. Tack J., Arts J., Caenepeel P. et al. Pathophysiology, diagnosis and management of postoperative dumping syndrome. Nat Rev Gastroenterol Hepatol. 2009; 6(10): 583–90.


About the Autors

Alexander S. Ametov, MD, professor, head of the Department of endocrinology of Russian medical academy of continuing professional education of the Ministry of Healthcare of Russia. Address: 125993, 2/1 build 1 Moscow Barrikadnaya Str. Tel.: +7 (495) 490-42-41.
Yuri E. Rubtsov, MD, clinic and Department of military field therapy of S.M. Kirov Military medical Academy of the Ministry of Defense of the Russian Federation. Address: 194044, St. Petersburg, 6 Academica Lebedeva Str. E-mail: rubtsovyuri@yandex.ru. eLibrary SPIN: 1096-5120.
Vladimir V. Salukhov, MD, professor, head of the first Department and clinic of therapy of improvement of doctors’ skills named after academician N.S. Molchanov of S.M. Kirov Military medical Academy of the Ministry of Defense of the Russian Federation. Address: 194044, St. Petersburg, 6 Academica Lebedeva Str. E-mail: vlasaluk@yandex.ru. eLibrary SPIN: 4531-6011.
Yuri S. Halimov, MD, professor, head of the Department of military field therapy of S.M. Kirov Military medical Academy of the Ministry of Defense of the Russian Federation. Address: 194044, St. Petersburg, 6 Academica Lebedeva Str. Tel: +7 (921) 941-18-56. Email: yushkha@gmail.com. eLibrary SPIN: 7315-6746.
Pavel V. Agafonov, PhD, the Department of military field therapy of S.M. Kirov Military medical Academy of the Ministry of Defense of the Russian Federation. Address: 194044, St. Petersburg, 6 Academica Lebedeva Str. E-mail: agafonov23@yandex.ru. eLibrary SPIN: 3303-4786.


Similar Articles

Back to Content

Бионика Медиа